Dihydropyridines: evaluation of their current and future pharmacological applications

Drug Discovery Today

Volumn 14, Issue 21-22, 2009, Pages 1058-1066

  Edraki, Najmeh ^a   Mehdipour, Ahmad R ^a   Khoshneviszadeh, Mehdi ^a   Miri, Ramin ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; AMLODIPINE; BREAST CANCER RESISTANCE PROTEIN; CALCIUM CHANNEL; CARBAMAZEPINE; GLYCOPROTEIN P; MINERALOCORTICOID RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE;

ALZHEIMER DISEASE; ANALGESIA; ANGINA PECTORIS; ANTICONVULSANT ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN VASOSPASM; BRONCHODILATATION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISOMERISM; LIVER PROTECTION; MIGRAINE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAYNAUD PHENOMENON; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; VASODILATATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DIHYDROPYRIDINES; DRUG RESISTANCE, MULTIPLE; HUMANS; NITRATES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350396600     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.08.004     Document Type: Review

References (79)

1. Eisner U., and Kuthan J. The chemistry of dihydropyridine. Chem. Rev. 72 (1972) 1-42
2. Safak C., and Simsek R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini Rev. Med. Chem. 6 (2006) 747-755
3. López-Arrieta J.M., and Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 3 (2002) CD000147
4. Young G.P. Calcium channel blockers in emergency medicine. Ann. Emerg. Med. 13 (1984) 712-722
5. Gordeev M.F., et al. Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorg. Med. Chem. 6 (1998) 883-889
6. Zamponi G.W. Antagonist binding sites of voltage-dependent calcium channels. Drug Dev. Res. 42 (1998) 131-143
7. Dolphin A.C. A short history of voltage-gated calcium channels. Br. J. Pharmacol. 147 Suppl. 1 (2006) S56-S62
8. Bean B.P. Classes of calcium channels in vertebrate cells. Annu. Rev. Physiol. 51 (1989) 367-384
9. Hess P. Calcium channels in vertebrate cells. Annu. Rev. Neurosci. 13 (1990) 337-356
10. Coburn R.A., et al. 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J. Med. Chem. 31 (1988) 2103-2107
11. Glossmann H., et al. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine. J. Cardiovasc. Pharmacol. 6 Suppl. 4 (1984) S608-S621
12. 2+ channel: model construction and docking calculations. J. Med. Chem. 50 (2007) 1504-1513
13. 2+ channel. Mol. Pharmacol. 63 (2003) 499-511
14. 2+ channel modulation by agonists and antagonists. Arch. Biochem. Biophys. 393 (2001) 22-41
15. Goldmann S., and Stoltefuss J. 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and agonist activities. Angew. Chem. Int. Ed. 30 (1991) 1559-1578
16. 2+ -antagonistic inhibitor of electromechanical coupling processes in mammalian myocardium. Arzneimittelforschung 22 (1972) 22-33
17. 2+ antagonism and thromboxane A2 synthase inhibition. J. Med. Chem. 36 (1993) 2964-2972
18. Vaghy P.L., et al. Receptor pharmacology of calcium entry blocking agents. Am. J. Cardiol. 59 (1987) 9A-17A
19. Glossmann H., et al. Calcium channels and calcium channel drugs: recent biochemical and biophysical findings. Arzneimittelforschung 35 (1985) 1917-1935
20. Matowe W.C., et al. AK-2-38, a nifedipine analogue with potent smooth muscle calcium antagonist action and partial agonist effects on isolated guinea pig left atrium. Proc. West. Pharmacol. Soc. 32 (1989) 305-307
21. Vo D., et al. Syntheses, calcium channel agonist-antagonist modulation effects, and nitric oxide release studies of [3-(benzenesulfonyl)furoxan-4-yloxy]alkyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-trifluoromethylphenyl, benzofurazan-4-yl, 2-, 3-, or 4-pyridyl)-3-pyridinecarboxylates. Drug Dev. Res. 56 (2002) 1-16
22. Vo D., et al. Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers. J. Med. Chem. 38 (1995) 2851-2859
23. Vo D., et al. Synthesis and cardioselective beta-adrenergic antagonist activity of quinolyloxypropanolamines. Drug Des. Discov. 9 (1992) 69-78
24. Rose U., and Drager M. Synthesis, configuration, and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates. J. Med. Chem. 35 (1992) 2238-2243
25. Lamas S., et al. Nitric oxide: from discovery to the clinic. Trends Pharmacol. Sci. 19 (1998) 436-438
26. Miri R., et al. Synthesis and calcium channel modulating effects of modified Hantzsch nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(pyridinyl or 2-trifluoromethylphenyl)-5-pyridinecarboxylates. Drug Dev. Res. 51 (2000) 225-232
27. Ogawa T., et al. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position. Chem. Pharm. Bull. (Tokyo) 41 (1993) 108-116
28. Furuta T., et al. Cardiovascular effects of FR34235, a new dihydropyridine slow channel blocker, in isolated rabbit myocardium and aorta. J. Cardiovasc. Pharmacol. 5 (1983) 836-841
29. Kerins D., et al. Drugs used for the treatment of myocardial ischemia. In: Hardman J., et al. (Ed). Goodman & Gilman's The Pharmacological Basis of Therapeutics (2001), McGraw-Hill 843-870
30. Jauk B., et al. Design and synthesis of a conformationally rigid mimic of the dihydropyrimidine calcium channel modulator SQ 32,926. Molecules 5 (2000) 227-239
31. Harrold M. Angiotensin converting enzyme inhibitors, antagonist and calcium channel blockers. In: Lemke T.L., and Williams D. (Eds). Foye's Principles of Medicinal Chemistry (2002), Lippincott Williams & Wilkins 533-561
32. Mohajeri A., et al. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS. J. Mol. Graph. Model. 26 (2008) 1057-1065
33. Mojarrad J.S., et al. Design and synthesis of methyl 2-methyl-7,7-dihalo-5-phenyl-2-azabicyclo[4.1.0]hept-3-ene-4-carboxylates with calcium channel antagonist activity. Bioorg. Med. Chem. 12 (2004) 3215-3220
34. Dagnino L., et al. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates. J. Med. Chem. 29 (1986) 2524-2529
35. Hemmateenejad B., et al. Conformational analysis of some new derivatives of 4-nitroimidazolyl-1,4-dihydropyridine-based calcium channel blockers. J. Mol. Struct.-Theochem. 717 (2005) 139-152
36. Miri R., et al. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg. Med. Chem. 14 (2006) 4842-4849
37. Mahmoudian M., and Richards W. A conformational distinction between dihydropyridine calcium agonists and antagonists. J. Chem. Soc. Chem. Commun. 10 (1986) 739-741
38. 2+ channel block by dihydropyridines: no modulation by the voltage protocol. Eur. J. Pharmacol. 309 (1996) 317-321
39. Rovnyak G.C., et al. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J. Med. Chem. 38 (1995) 119-129
40. Franckowiak G., et al. The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur. J. Pharmacol. 114 (1985) 223-226
41. Mahmoudian M., and Richards W.G. QSAR of binding of dihydropyridine-type calcium antagonists to their receptor on ileal smooth muscle preparations. J. Pharm. Pharmacol. 38 (1986) 272-276
42. Mahmoudian M., and Richards W.G.A. Quantum chemical study of structure-activity relationships of dihydropyridine calcium antagonists. J. Sci. Technol. I. R. Iran 1 (1990) 261-265
43. Gaudio A.C., et al. Quantitative structure-activity relationships for 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues): a quantum chemical/classical approach. J. Pharm. Sci. 83 (1994) 1110-1115
44. Hemmateenejad B., et al. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method. Arch. Pharm. (Weinheim) 335 (2002) 472-480
45. Hemmateenejad B., et al. QSAR study of the calcium channel antagonist activity of some recently synthesized dihydropyridine derivatives. An application of genetic algorithm for variable selection in MLR and PLS methods. Chemom. Intell. Lab. Syst. 64 (2002) 91-99
46. Hemmateenejad B., et al. Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous). J. Chem. Inf. Comput. Sci. 43 (2003) 1328-1334
47. Safarpour M.A., et al. Quantum chemical-QSAR study of some newly synthesized 1,4-dihydropyridine calcium channel blockers. QSAR Comb. Sci. 22 (2004) 997-1005
48. Schleifer K.J., and Tot E. CoMFA, CoMSIA and GRID/GOLPE studies on calcium entry blocking 1,4-dihydropyridines. Quant. Struct.-Act. Rel. 21 (2002) 239-248
49. Tsuruo T., et al. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem. Pharmacol. 31 (1982) 3138-3140
50. Tsuruo T., et al. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43 (1983) 2905-2910
51. Philip P.A., et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br. J. Cancer 65 (1992) 267-270
52. Coburger C., et al. Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. Pharm. Res. 26 (2009) 182-188
53. Fusi F., et al. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets 7 (2006) 949-959
54. Richter M., et al. Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells. J. Med. Chem. 49 (2006) 2838-2840
55. Saponara S., et al. 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart. Eur. J. Pharmacol. 563 (2007) 160-163
56. Voigt B., et al. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors. Bioorg. Med. Chem. 15 (2007) 5110-5113
57. Tasaka S., et al. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg. Med. Chem. Lett. 11 (2001) 275-277
58. Zhou X.F., et al. Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J. Pharm. Sci. 94 (2005) 2256-2265
59. Zhou X.F., et al. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab. Dispos. 33 (2005) 1220-1228
60. Zhou X.F., et al. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab. Dispos. 33 (2005) 321-328
61. Ford J.M., and Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42 (1990) 155-199
62. Foroughinia F., et al. Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3,5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity. J. Pharm. Pharmacol. 60 (2008) 1481-1489
63. Mehdipour A.R., et al. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem. Biol. Drug Des. 70 (2007) 337-346
64. Miri R., and Mehdipour A. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR. Bioorg. Med. Chem. 16 (2008) 8329-8334
65. Triggle D.J. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol. 23 (2003) 293-303
66. Mannhold R. KATP channel openers: structure-activity relationships and therapeutic potential. Med. Res. Rev. 24 (2004) 213-266
67. Dietz J.D., et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51 (2008) 742-748
68. Kaminski R.M., et al. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. Pharmacol. Biochem. Behav. 68 (2001) 661-668
69. Yiu S.H., and Knaus E.E. Synthesis of valproate, valerate, and 1-methyl-1,4-dihydropyridyl-3-carbonyloxy ester derivatives of Hantzsch 1,4-dihydropyridines as potential prodrugs and their evaluation as calcium channel antagonist and anticonvulsant agents. Drug Dev. Res. 48 (1999) 26-37
70. Jiang J.L., et al. 6-Phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 39 (1996) 4667-4675
71. van Rhee A.M., et al. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J. Med. Chem. 39 (1996) 2980-2989
72. Desai B., et al. Synthesis and QSAR studies of 4-substituted phenyl-2,6-dimethyl-3,5-bis-N-(substituted phenyl)carbamoyl-1,4-dihydropyridines as potential antitubercular agents. Bioorg. Med. Chem. 9 (2001) 1993-1998
73. Khoshneviszadeh M., et al. Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg. Med. Chem. 17 (2009) 1579-1586
74. Raghavan K.S., et al. Improved delivery through biological membranes. XXX. Synthesis and biological aspects of a 1,4-dihydropyridine based chemical delivery system for brain-sustained delivery of hydroxy CCNU. Anticancer Drug Des. 2 (1987) 25-36
75. El-Sherbeny M.A., et al. Synthesis, in vitro and in vivo evaluation of a delivery system for targeting anticancer drugs to the brain. Arch. Pharm. (Weinheim) 336 (2003) 445-455
76. Briede J., et al. Effect of new and known 1,4-dihydropyridine derivatives on blood glucose levels in normal and streptozotocin-induced diabetic rats. Cell Biochem. Funct. 22 (2004) 219-224
77. Kobayashi S., et al. Inhibitory effect of nifedipine on tumor necrosis factor alpha-induced neovascularization in cultured choroidal explants of streptozotocin-diabetic rat. Biol. Pharm. Bull. 28 (2005) 242-246
78. Chhillar A.K., et al. Microwave-assisted synthesis of antimicrobial dihydropyridines and tetrahydropyrimidin-2-ones: novel compounds against aspergillosis. Bioorg. Med. Chem. 14 (2006) 973-981
79. Das P., et al. Inhibition of type A GABA receptors by L-type calcium channel blockers. Neuroscience 124 (2004) 195-206